According to the Chief Medical Officer and Head of Global Product Development at Roche, Levi Garraway, MD, PhD, since follicular lymphoma often needs lifelong management, decreasing the burden of care for such individuals is indeed of major importance. Due to this FDA approval, treatment can now be administered in about one minute, which prominently decreases the time patients spend within the clinic and helps to sync care along with their individual requirements as well as preferences.

It is well to be noted that VELO decreases the treatment administration time with an approx. one-minute injection as compared with a 2-4 hour intravenous (IV) infusion. Like Lunsumio, which is administered intravenously, Lunsumio VELO by Roche can be administered outpatient and is a fixed-duration treatment that is given for a defined period, and that could be as short as six months. By contrast, treat-to-progression treatment alternatives are designed to be given to patients indefinitely until the time of disease progression or till treatment can no longer be tolerated. Tennessee Oncology and One Oncology’s Dr. Ian Flinn, MD, PhD, says that this approval is a major step when it comes to broadening access to effective treatments for people who are living with follicular lymphoma. Due to its manageable cytokine release syndrome profile as well as decreased administration time, Lunsumio VELO helps oncologists to roll out advanced care across the community practice settings.

Interestingly, the FDA approval has received support from the primary analysis of the GO29781 study, which evaluated Lunsumio VELO across patients having third-line or later (3L+ FL). Inferences showed that the objective response rate as well as the complete response rate within patients treated with Lunsumio VELO were 75% (95% confidence interval [CI]: 64–83%) and 59% (95% CI: 48–69%), respectively. The median duration when it comes to response was 22.4 months – 95% CI: 16.8–22.8. The most common adverse reactions (≥20%) were the injection site reactions, such as fatigue, rash, cytokine release syndrome (CRS), COVID-19 infection, and musculoskeletal pain, as well as diarrhea. Notably, the CRS rate was 30%, and events were mostly low grade, i.e., Grade 1–2 (28%) and Grade 3 (2.1%) occurred in Cycle 1, and all resolved post a median duration of two days (range: 1–15). Apparently, CRS can be severe as well as life-threatening.

It is well to be noted that Lunsumio IV was the first bispecific antibody that was approved for 3L+ FL. Long-term data from the SC as well as IV arms of the GO29781 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition. These data have been submitted to other healthcare authorities throughout the world. Recently, the European Commission went on to grant a conditional marketing authorization of Lunsumio SC when it comes to the treatment of adult patients having R/R FL post two or more lines of systemic therapy.

Roche goes on to advance its bispecific antibody programme within the gamut of lymphoma, with ongoing phase III studies assessing Lunsumio and Lunsumio VELO within the earlier lines of treatment. This goes on to include the SUNMO study, which investigates the Lunsumio VELO in combination with Polivy® (polatuzumab vedotin) in the second-line or later large B-cell lymphoma, as well as the MorningLyte study, which investigates the Lunsumio VELO in combination with lenalidomide in past untreated FL.

HRT has long been used to ease menopausal symptoms, but its usage fell sharply in the early 2000s after the FDA issued boxed warnings based on a Women’s Health Initiative study. That study reported a statistically non-significant rise in breast cancer diagnoses, involved participants with an average age of 63 years, well beyond the typical onset of menopause, and used a hormone formulation that is no longer standard.

Following a full scientific review, an expert panel meeting in July, and a public comment process, the FDA is now moving to remove those broad black box warnings. The agency is coordinating with manufacturers to revise product labels and eliminate references to risks involving cardiovascular disease, breast cancer, and probable dementia. One exception remains: the boxed warning for endometrial cancer will stay in place for systemic estrogen-alone medications.

As estrogen and progesterone decline during menopause, FDA-approved HRT, whether estrogen-progesterone combinations or estrogen alone for women without a uterus, can be used to address symptoms such as night sweats, hot flashes, bone loss, and sleep disruption.

Randomized studies indicate that starting HRT within 10 years of menopause onset, typically before age 60, can lower all-cause mortality and fracture risk. Women may also see reductions of up to 50% in cardiovascular diseases, a 35% decrease in Alzheimer’s disease, and a 50 to 60% drop in bone fractures. The FDA’s guidance continues to recommend initiating systemic HRT before age 60 or within a decade of menopause onset, with final decisions resting between patients and their clinicians.

Alongside the warning changes, the FDA has approved two new treatments for menopause-related symptoms. One is a generic version of Premarin (conjugated estrogens), marking the first such approval in more than 30 years and expected to improve access while matching the brand’s quality and effectiveness. The second is a non-hormonal therapy designed for moderate to severe vasomotor symptoms, offering an alternative for women who cannot or prefer not to take hormone therapy.

The executive order will address around 26 medications considered “especially critical to the health and security interests of the nation” These drugs are to be included in the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a program originally established during President Trump’s first term.

“Filling the SAPIR will insulate the United States from the concentration of foreign, sometimes adversary, nations in the world-wide supply of the key starting materials used to make APIs. the order states. Through these ingredients, the government seeks to wean the country away from foreign sources while ensuring continued access to critical treatments.

The order also highlights that “Moreover, Government purchases of APIs to fill the SAPIR can encourage more domestic production of APIs.” 

SAPIR is managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within HHS. When first implemented, SAPIR identified 86 medications critical for acute care that lacked suitable alternatives. The initial list included Pfizer/Bristol Myers Squibb’s Eliquis (apixaban), Gilead’s HIV treatment Biktarvy (bictegravir), and Amgen’s Neupogen (filgrastim).

Under the current executive order, ASPR has been instructed to produce a new, narrower list of critical drugs within 30 days. This review will explore how current funding can maintain a six-month stock of APIs, with emphasis on domestic manufacturing sources to strengthen US Pharma Supply Chain.

This move is part of a larger US policy to increase domestic pharmaceutical production and manufacturing and boost the US Pharma Supply Chain. It is supplemented by efforts like the FDA PreCheck program that expedites approval for companies building new US plants. Just 11 percent of APIs are now manufactured in the US, but with AbbVie and Lilly committing fresh investment and following the tariff plans, this proportion is set to increase over next few years.